|Synonyms||ABC-294640; ABC 294640; 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide.|
|Description||ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, ABC294640 competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation.|
|Current Developer||Apogee Biotechnology Corporation.|
MP-A08 is a cell permeable selective inhibitor of sphingosine kinase 2 (Ki=6.9 μM) and 1 (Ki=27 μM) with little affinity for other kinases. In vitro: inhibits c...
The hydrochloride salt form of SLP120701, an oxadiazol derivative, has been found to be a Sphk inhibitor and could probably be useful in studies of some cancer,...
Cell-permeant reversible inhibitor of SphK1 (IC50 value 2.0 nM; Ki value 3.6 nM). PF-543 is sphingosine-competitive and is more than 100-fold selective for SphK...
ABC294640 is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon adm...
VT-ME6 is a selective sphingosine kinase 2 inhibitor. VT-ME6 shows three-fold selectivity for SphK2 over SphK1. It has a quaternary ammonium group which is nece...
2-(p-Hydroxyanilino)-4-(p-chlorophenyl)thiazole (SK1-II) is a cell permeable, potent, and specific inhibitor of sphingosine kinase (IC50 = 0.5 μM). The compound...
PF-543 is a novel selective SK-1 inhibitor which inhibited SK-1 activity in a competitive manner with sphingosine. PF-543 inhibits SphK1 with a K(i) of 3.6 nM, ...
K145 is a selective sphingosine kinase-2 (SphK2) inhibitor and anticancer agent. K145 inhibited the activity of SphK2 in a dose-dependent manner with an IC50 of...
The hydrochloride salt form of SLR080811, an oxadiazol derivative, has been found to be a SphK inhibitor and could probably be useful in studies of some cancer,...
SLR080811, an oxadiazol derivative, has been found to be a SphK inhibitor and could probably be useful in studies of some cancer, fibrosis, and sickle cell dise...
K145 (3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione) is a selective inhibitor of sphingosine kinase-2 (SphK2) and an anticancer ...